An observational study in Brachytherapy, Uterine Cervical Neoplasms and Uterine Neoplasms, sponsored by Zhejiang Cancer Hospital. Recruiting at 1 site in China. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-02-16.
Sponsored by Zhejiang Cancer Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Uterine Cervical Neoplasms by Zhejiang Cancer Hospital — 5 open to participants now, 5 under way, 1 of them phase 3. Uterine Cervical Neoplasms · Zhejiang Cancer Hospital.
Among the 10 studies in Uterine Cervical Neoplasms by Zhejiang Cancer Hospital, this one is one of 3 that started in 2022, is one of 2 observational ones, and was the 6th registered.
2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.
Browse Uterine Cervical Neoplasms studies →5 of the 10 studies in Uterine Cervical Neoplasms by Zhejiang Cancer Hospital are open now, in 1 country. Recruiting first, the newest first:
Zhejiang Cancer Hospital · Sites in China
Ages 18+ · Women only
Zhejiang Cancer Hospital · Sites in China
Ages 18–75 · Women only
Zhejiang Cancer Hospital
Ages 18+ · Women only
Zhejiang Cancer Hospital
Ages 18–75 · Women only
By country, each count listing its studies:
Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.
This study: 18 Years to 80 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 220 across 530 observational studies indexed under Uterine Cervical Neoplasms.
Median enrollment 52 across the 8 interventional studies, 180 across the 2 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Zhejiang Cancer Hospital is the lead sponsor of 282 studies on the registry; 117 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Uterine Cervical Neoplasms by Zhejiang Cancer Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Brachytherapy for gynecological cancers will be studied retrospectively.
18 to 80 years old female who diagnosed as gynecological cancer and underwent brachytherapy will be enrolled in this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Radiation: Brachytherapy
Radiation: Brachytherapy
Radiation: Brachytherapy
Radiation: Brachytherapy
Radiation: Brachytherapy
Applicator, dose, schedule, technology, image, 3D print, efficacy, toxicity of brachytherapy
Overall survival rate
the percentage of participants in the group who survives
Time frame: 5-year
Progression-free survival rate
the percentage of participants in the group whose disease is likely to remain stable
Time frame: 5-year
Side effects
side effects associated with treatment
Time frame: 5-year
Start is estimated for Feb 2022; primary completion for Dec 2024, 34 months later.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.